Can Basal Cell Carcinoma Come Back in the Same Spot?

Basal cell carcinoma can absolutely come back in the same spot after treatment, and it does so more often than many patients expect. Recurrence rates range from about 1% to over 10% within five years, depending heavily on the treatment method, the tumor’s biology, and where on the body it grew. The fact that a tumor was fully removed once does not make that site immune to regrowth, and understanding what drives recurrence helps you know what to watch for and when to worry.

How Often Does BCC Come Back?

Recurrence rates vary widely because not all treatments clear the tumor with equal reliability. Mohs micrographic surgery, which checks margins under a microscope in real time, has the lowest recurrence rates. A large Spanish registry tracking over 4,400 patients treated with Mohs surgery found a recurrence rate of about 1.3 per 100 person-years of follow-up, with the risk holding roughly steady for at least the first five years.¹ A Dutch study looking specifically at aggressive and recurrent facial BCCs put the five-year recurrence rate after Mohs at about 2% for previously untreated tumors and around 5% for tumors that had already recurred once before.²

Standard surgical excision, the most common treatment, sits somewhere in the middle. One retrospective study from a tertiary center found a recurrence rate of about 6% in patients followed for at least three years.³ That number climbs when surgical margins are positive, meaning tumor cells were found at the edge of the excised tissue.⁴

Curettage and electrodesiccation, a scrape-and-burn technique often used for small, low-risk BCCs, carries higher recurrence risk. A nationwide Dutch cohort study of over 47,000 tumors found a five-year recurrence rate of about 10%, rising to roughly 13% at eight years.⁵ When curettage and electrodesiccation is used on aggressive histologic subtypes, the problem gets worse: one study reported a 27% recurrence rate for aggressive BCCs treated this way.⁶

Radiation therapy, reserved mainly for patients who are poor surgical candidates, also carries meaningful recurrence risk. A study of 448 non-melanoma skin cancers treated with radiotherapy found an overall recurrence rate of nearly 16%, with tumor size, patient age, and immunosuppression all influencing the outcome.⁷

What Makes Recurrence More Likely

Not all BCCs carry the same recurrence risk. Several features push that risk upward, and they tend to cluster together in the tumors that cause the most trouble.

Histologic subtype matters a great deal. Aggressive growth patterns, such as infiltrating, morpheaform, and micronodular subtypes, are harder to clear because their borders are irregular and often extend further than they look clinically. A study of periocular BCCs found that three-quarters of recurring tumors had aggressive subtypes, compared with about half of non-recurring ones. Among patients who experienced multiple recurrences, every single one had an aggressive subtype.⁸ In a randomized trial comparing Mohs surgery with standard excision for facial BCCs, aggressive histologic subtype was a significant risk factor for recurrence in tumors that had already been treated once before.⁹

Location plays a similarly important role. BCCs on the head and neck recur far more often than those on the trunk or limbs. In the large Dutch curettage cohort, head and neck tumors had a recurrence rate of about 25% at eight years, more than double the rate for tumors elsewhere on the body.⁵ The nose, the area around the eyes, and the ears are particularly problematic because the skin there is thin, the anatomy is complex, and subclinical tumor extensions tend to be wider.

Tumor size matters as well. Tumors larger than about 1 centimeter have higher recurrence rates, and the size of the original lesion also predicts how much additional tissue will need to be removed if the tumor does come back.⁷ Research on Mohs surgery has shown that recurrent BCCs require more surgical stages and produce larger final defects than tumors being treated for the first time.¹⁰

Perineural invasion, where tumor cells grow along nerve fibers, is another worrisome feature. When present, it tends to occur alongside other high-risk characteristics: larger tumors, aggressive subtypes, and facial location. The five-year recurrence risk is higher when perineural invasion is identified, though some research suggests its independent contribution may be modest once other high-risk features are accounted for.¹¹¹²

The Role of Surgical Margins

Whether the surgeon achieved clear margins is one of the strongest predictors of whether a BCC will return. “Clear margins” means the pathologist found no tumor cells at the edges of the removed tissue. When margins are positive or narrowly clear, the odds of recurrence jump.

A systematic review of excision margins found that wider margins produce higher rates of complete excision. A 5 mm clinical margin achieved a complete excision rate of about 95%, while narrower margins of 2 mm dropped that rate to roughly 88%.¹³ A multi-center analysis using natural language processing to review pathology reports found that a 6 mm clinical peripheral margin was needed to reach a 95% histological clearance rate, and this held true for both high-risk and low-risk BCCs.¹⁴

This is one reason Mohs surgery performs so well: it examines 100% of the surgical margin during the procedure, whereas conventional pathology examines only a small sample. Mohs essentially guarantees that no visible tumor cells remain. Standard excision, by contrast, may leave behind microscopic tumor that the pathology bread-loafing technique misses.

When Recurrences Show Up

Most recurrences appear within the first few years after treatment. A classic overview of BCC recurrence found that the highest risk window falls between one and four years after therapy.¹⁵ A retrospective study found the average time from initial surgery to recurrence was about 31 months, though some tumors came back as early as 11 months and others took over seven years to reappear.¹⁶

This timeline explains why dermatologists recommend follow-up skin checks for at least five years after treatment, with most guidelines suggesting visits every six to twelve months during the high-risk window. The Spanish Mohs registry echoed this, concluding that follow-up should be equally intense for at least the first five years, with extra attention to tumors that were non-primary, required multiple surgical stages, or involved unfinished procedures.¹ Late recurrences beyond five years do happen, which is why many clinicians recommend ongoing annual skin exams indefinitely.

True Recurrence Versus a New Tumor in the Same Area

There is an underappreciated wrinkle in recurrence data: not every BCC that shows up near a treatment site is a true recurrence. Some are entirely new tumors that happen to arise in the same sun-damaged skin. Distinguishing between the two is harder than it sounds.

A study examining supposed recurrences after complete surgical excision raised this exact question. Two-thirds of the possible and probable recurrences occurred in the temple and forehead, even though those sites accounted for only about a fifth of all lesions. The authors suggested that many of these “recurrences” may actually have been new primary tumors arising in an area of field change, where chronic sun damage had primed multiple cells for malignant transformation, rather than true regrowth of residual disease.¹⁷

The distinction matters clinically. A true recurrence implies that the original treatment left behind microscopic tumor, while a new primary tumor reflects ongoing UV-driven damage that would have happened regardless. From a patient’s perspective, the practical implication is the same: you need treatment. But a true recurrence tends to behave more aggressively and may need a more robust approach than the original treatment provided.

Treating a BCC That Has Already Come Back

When a BCC recurs, it is generally treated more aggressively than a first-time tumor. The evidence strongly favors Mohs surgery for recurrent BCCs. In the Dutch randomized trial comparing Mohs with standard excision, about 2% of recurrent BCCs treated with Mohs came back again, compared with roughly 12% of those treated with standard excision.⁹

The reason Mohs works better for recurrences is partly practical. Scar tissue from the original treatment distorts the anatomy and makes it harder to judge where tumor ends and normal tissue begins. Mohs provides real-time margin assessment, allowing the surgeon to chase tumor extensions that would be invisible during a standard excision. Research confirms that recurrent tumors require more surgical stages and result in larger wounds than first-time tumors, so the process tends to be more involved.¹⁰

BCCs that recur after radiation therapy present a particularly stubborn problem. These tumors tend to be large, aggressive, and invasive, and they have high re-recurrence rates after standard surgical excision or further radiation. Even with Mohs surgery, one study of post-radiation recurrences reported a re-recurrence rate of about 7%, with the tumors averaging over 2 cm in size and frequently located in the mid-face.¹⁸

When Surgery Is Not an Option

A small percentage of BCCs become locally advanced to the point where surgery would be impractical or disfiguring, or they recur repeatedly despite multiple procedures. For these patients, hedgehog pathway inhibitors have changed the landscape. Vismodegib and sonidegib target the molecular signaling pathway that drives the vast majority of BCCs.

A systematic review pooling data from multiple studies found that vismodegib produced a complete or partial response in about 62% of patients with locally advanced BCC. Complete responses occurred in roughly 28% of cases, with partial responses in another 34%.¹⁹ A real-world single-center study looking at both vismodegib and sonidegib found a similar overall response rate of about 62%, with roughly 45% achieving a complete response. However, about 28% of complete responders later experienced recurrence or new BCCs.²⁰

These drugs are not cures in most cases. They can shrink tumors enough to make surgery feasible, or they can control disease in patients who have run out of surgical options. Side effects, particularly muscle cramps, taste changes, and hair loss, lead some patients to stop treatment. The approach for patients in this category requires individualized, highly specialized care, often involving dermatologists, surgeons, and oncologists working together.²¹

Spotting a Recurrence in Scar Tissue

One of the challenges with BCC recurrence is that it can be tricky to identify visually. A BCC growing back in a surgical scar may look like nothing more than a slightly shiny area or a subtle change in the scar’s texture. Traditional dermoscopy helps, but scar tissue and post-surgical changes can mimic or mask the features that would normally raise suspicion.

Newer imaging tools are proving useful. Reflectance confocal microscopy, which provides cellular-level images of the skin without a biopsy, showed a positive predictive value of 92% for detecting recurrent BCC when looking for specific patterns of tumor cell streaming and stromal changes.²² Optical coherence tomography, which images slightly deeper into the skin, has also shown promise for detecting residual BCC beneath and around scars, where biopsy-induced changes can make confocal microscopy alone less reliable.²³

These technologies are not yet standard equipment in every dermatology office, but they are increasingly available in academic centers and specialized skin cancer clinics. For patients who have had multiple BCCs or whose treatment sites look suspicious but ambiguous, these tools can reduce the need for repeat biopsies while catching recurrences earlier.

BCC Growing in Scars From Other Causes

An unusual but documented phenomenon is BCC arising within scar tissue unrelated to a prior BCC, such as burn scars, surgical scars from unrelated procedures, and even vaccination scars. The mechanisms behind this are still not fully understood, though chronic inflammation, altered immune surveillance in scar tissue, and disrupted skin architecture have all been proposed as contributing factors.²⁴ This is rare enough that most patients do not need to worry about it, but it is a reminder that scar tissue is not biologically inert. Any persistent or changing lesion within a scar deserves evaluation, regardless of the scar’s origin.

Genetic Patterns Behind High-Risk Tumors

Research is beginning to uncover the molecular differences between BCCs that behave aggressively and those that do not. A whole exome sequencing study comparing high-risk and low-risk BCCs found that certain gene mutations were more common in high-risk tumors. LRP1B was the most frequently mutated gene in high-risk BCCs, while SMO mutations were more common in low-risk tumors. Mutations in PTCH1, KMT2C, NSD1, and ARID1A were also more frequent in the high-risk group.²⁵

This kind of genetic profiling is not yet part of routine BCC management. You will not get a genomic test alongside your biopsy at a typical dermatology visit. But as these patterns become clearer, they may eventually help clinicians predict which BCCs deserve more aggressive initial treatment, potentially reducing the number that come back. For now, the decision about how aggressively to treat relies on the clinical and histologic risk factors already discussed: subtype, location, size, and margin status.

1
PubMed Central. Risk Factors and Rate of Recurrence after Mohs Surgery in Basal Cell and Squamous Cell Carcinomas: A Nationwide Prospective Cohort (REGESMOHS, Spanish Registry of Mohs Surgery)
2
Acta Dermato-Venereologica. 5-year Recurrence Rates of Mohs Micrographic Surgery for Aggressive and Recurrent Facial Basal Cell Carcinoma
3
PubMed Central. Clinical Characteristics of Local Recurrent Basal Cell Carcinoma After Surgical Excision: A Retrospective Study of the Patients From a Tertiary Clinical Center
4
PubMed Central. Recurrence rate of basal cell carcinoma with positive histopathological margins and related risk factors
5
PubMed Central. Long-term Recurrence after Curettage ± Electrodesiccation for Basal Cell Carcinoma: A Nationwide Cohort Study of 47,358 Tumours from Dermatology Practices
6
PubMed. Recurrence rates of aggressive histologic types of basal cell carcinoma after treatment with electrodesiccation and curettage alone
7
PubMed Central. Predictors of recurrence after radiotherapy for non-melanoma skin cancer
8
PubMed Central. Aggressive subtypes in basal cell carcinomas might need different treatment and follow-up due to the higher risk of surgically uncontrollable recurrences
9
The Lancet Oncology. Surgical excision versus Mohs’ micrographic surgery for primary and recurrent basal-cell carcinoma of the face
10
Acta Dermato-Venereologica. Mohs Micrographic Surgery for Primary Versus Recurrent or Incompletely Excised Facial High-risk Basal Cell Carcinomas
11
PubMed. Basal cell carcinoma treated with Mohs surgery in Australia III. Perineural invasion
12
Journal of the American Academy of Dermatology. Histologic perineural invasion of unnamed nerves does not affect basal cell carcinoma outcomes
13
PubMed Central. Surgical Margin of Excision in Basal Cell Carcinoma: A Systematic Review of Literature
14
Journal of Plastic, Reconstructive & Aesthetic Surgery. Re-evaluating surgical excision margins in basal cell carcinoma in the context of updated Royal College of Pathologists reporting standards
15
PubMed. Recurrence rates of treated basal cell carcinomas. Part 1: Overview
16
PubMed Central. Recurrent cutaneous basal cell carcinoma after surgical excision: A retrospective clinicopathological study
17
PubMed. Do basal cell carcinomas recur after complete conventional surgical excision?
18
PubMed. Basal cell carcinoma recurring after radiotherapy: a unique, difficult treatment subclass of recurrent basal cell carcinoma
19
JAMA Dermatology. Hedgehog Pathway Inhibitor Therapy for Locally Advanced and Metastatic Basal Cell Carcinoma: A Systematic Review and Pooled Analysis of Interventional Studies
20
PLoS ONE. Hedgehog pathway inhibitors for locally advanced and metastatic basal cell carcinoma: A real-world single-center retrospective review
21
PubMed Central. Management of high-risk and advanced basal cell carcinoma
22
PubMed. The reflectance confocal microscopy in diagnosis of recurrent basal cell carcinoma
23
JAMA Dermatology. Evaluation of a Combined Reflectance Confocal Microscopy–Optical Coherence Tomography Device for Detection and Depth Assessment of Basal Cell Carcinoma
24
PubMed Central. Basal Cell Carcinoma: Comprehensive Review with Emphasis on Scar Tissue Manifestation and Post-Vaccination Incidence
25
PubMed Central. Investigation of Genetic Mutations in High-risk and Low-risk Basal Cell Carcinoma in a Non-Caucasian Population by Whole Exome Sequencing